Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1636 1639 1675 1684
This examiner grants 75% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17777922 | METHOD OF DESIGNING CARBOHYDRATES | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 17912373 | UMI AND APPLICATION THEREOF, MOLECULAR IDENTIFIER GROUP, ADAPTER, ADAPTER LIGATION REAGENT, KITS, METHOD FOR CONSTRUCTING DNA LIBRARY AND METHOD FOR SEQUENCING GENE | Non-Final OA | BOE TECHNOLOGY GROUP CO., LTD. |
| 17759917 | Systems and Methods to Identify Genetic Silencers and Applications Thereof | Non-Final OA | The Board of Trustees of the Leland Stanford Junior University |
| 18067900 | CO-PACKAGING TO MITIGATE INTERMOLECULAR RECOMBINATION | Non-Final OA | MASSACHUSETTS INSTITUTE OF TECHNOLOGY |
| 18189704 | METHOD FOR CONSTRUCTING CHIMERIC PLASMID LIBRARY | Non-Final OA | NATIONAL UNIVERSITY CORPORATION KOBE UNIVERSITY |
| 17906940 | IDENTIFICATION AND USE OF COMPOUNDS IN THE TREATMENT OR PREVENTION OF SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 | Non-Final OA | Vanda Pharmaceuticals Inc. |
| 17914373 | USE OF BIOMARKERS IN THE TREATMENT OF FIBROTIC CONDITIONS | Non-Final OA | Boehringer Ingelheim International GmbH |
| 18160407 | LIBRARIES OF GENETIC PACKAGES COMPRISING NOVEL HC CDR1, CDR2, AND CDR3 AND NOVEL LC CDR1, CDR2, AND CDR3 DESIGNS | Non-Final OA | Takeda Pharmaceutical Company Limited |
| 17980393 | PRIMER EXTENSION TARGET ENRICHMENT OF IMMUNE RECEPTOR SEQUENCES IN ALLOIMMUNE DISORDERS OF PREGNANCY | Non-Final OA | Roche Sequencing Solutions, Inc. |
| 17915771 | Methods and Tools for Studying Enteroendocrine Cells | Non-Final OA | Koninklijke Nederlandse Akademie Van Wetenschappen |
| 17802377 | METHODS AND COMPOSITIONS FOR IDENTIFYING TRAITS USING A CELL-FREE SYSTEM | Non-Final OA | Synvitrobio, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy